Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:32 PM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom cancer therapy using mRNA technology. Patients receiving the treatment with Keytruda went longer without cancer recurrence than those on Keytruda alone, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:27 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence, and shares surged 177%. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:22 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company's fundamentals and future prospects.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:17 PM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:12 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda, and the stock surged 177%, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:07 PM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:02 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda. This is a significant positive catalyst for the company, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 10:57 PM UTC

Segments 13-17 report that Moderna's personalized cancer treatment succeeded in a Phase 3 trial, showing longer time without cancer recurrence when combined with Keytruda. This is a material positive catalyst for Moderna, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 10:52 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 10:47 PM UTC

Segments 13-16 describe Moderna's Phase 3 cancer vaccine success, which led to a 177% share price surge, indicating a material positive catalyst for Moderna.